Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women

Circulation

Volumn 101, Issue 1, 2000, Pages 67-70

  Roest, Mark ^a,b,c   Van Der Schouw, Yvonne T ^a   Banga, Jan Dirk ^b   Tempelman, Mariëlle J ^b   De Groot, Philip G ^b   Sixma, Jan J ^b   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Cerebrovascular disorders; Mortality; Plasminogen activators

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEUROTOXICITY; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; STROKE;

EID: 0034602849     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.1.67     Document Type: Article

References (30)

1. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction [see comments]. Lancer. 1993;341:1165-1168.
2. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments]. N Engl J Med. 1995;332:635-641.
3. Juhan Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group: European Concerted Action on Thrombosis and Disabilities [see comments]. Circulation. 1996;94:2057-2063.
4. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study: Etude Cas-Temoins de l'Infarctus du Mycocarde. Thromb Haemost. 1995;74:837-841.
5. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke [see comments]. Lancet. 1994;343:940-943.
6. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989; 79:101-106.
7. Bashir SA, Duffy SW, Qizilbash N. Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors. Int J Epidemiol. 1997;26:64-70.
8. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
9. Ridker PM, Vaughan DE, Stampfer MJ, Sacks FM, Hennekens CH. A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100. Arterioscler Thromb. 1993;13:1-6.
10. Humphries SE, Panahloo A, Montgomery HE, Green F, Yudkin J. Geneenvironment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost. 1997;78:457-461.
11. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
12. Humphries SE, Green FR, Temple A, Dawson S, Henney A, Kellcher CH, Wilkes H, Meade TW, Wiman B, Hamsten A. Genetic factors determining thrombosis and fibrinolysis. Ann Epidemiol. 1992;2:371-385.
13. Shah PK, Falk E, Badimon JJ, Fernandez Ortiz A, Mailhac A, Villareal Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565-1569.
14. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet. 1996; 348(suppl 1):s7-s10.
15. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917-925.
16. Tsirka SE, Bugge TH, Degen JL, Strickland S. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. Proc Natl Acad Sci U S A. 1997;94:9779-9781.
17. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice [see comments]. Nat Med. 1998;4:228-231.
18. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
19. Ossei Geming N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol. 1997;17:33-37.
20. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.
21. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730-734.
22. Waard DF, Collette HJA, Rombach JJ, Baanders-van Halewijn EA, Honing C. The DOM project for early diagnosis of breast cancer. J Chronic Dis. 1984;47:41-44.
23. Roest M, Banga JD, de Valk B, Marx JJM, Tempelman MJT, de Groot PHG, Sixma JJ, van der Schouw YT. The factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women. Am J Epidemiol. 1999;149:665.
24. Mietinen OS. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103:181-235.
25. Hardy GH. Mendelian proportions in mixed population. Science. 1908; 28:41-50.
26. Weinberg W. On Demonstration of Heredity in Man: Papers of Human Genetics. Englewood Cliffs. NJ: Prentice Hall; 1963.
27. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. 1967;1:221-233.
28. Mietinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974;99:325-333.
29. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, Taioli E, Sansoni P, Bertolini S, Franceschi C. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins: a study in centenarians. Arterioscler Thromb Vasc Biol. 1997;17:755-759.
30. Dalstra JAA, Reitsma JB. Hart- en vaatziekten in Nederland 1997: Cijfers over ziekte en sterfte. Den Haag, Netherlands: Nederlandse Hartstichting; 1997.